INFECTIOUS EXACERBATION OF BRONCHIECTASIS SUCCESSFULLY TREATED WITH CEFTRIAXONE/SULBACTAM/DISODIUM EDETATE-1034 (ELORESâ„¢)

  • Parag Sharma

Abstract

ABSTRACT
Bronchiectasis is a type of chronic obstructive pulmonary disease, defined as permanent abnormal dilation of bronchi due to vicious cycle of transmural
infection and inflammation. Bronchiectasis is generally characterized by cough, wheeze, and dyspnea. Pathogens responsible for bronchiectasis
include pathogens Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, and nontuberculous
mycobacteria. Empirical antibiotic therapy and other drugs are used empirically in the management of bronchiectasis.Here, we discuss a case of
infectious exacerbation of bronchiectasis successfully treated with an empirical use of ceftriaxone/sulbactam/disodium edetate-1034.
Keywords: Bronchiectasis, Eloresâ„¢, Ceftriaxone/sulbactam/disodium edetate-1034, Disodium edetate, Antibiotic resistance.

References

REFERENCES
1. Rabe KF. Guidelines for chronic obstructive pulmonary disease
treatment and issues of implementation. Proc Am Thorac Soc
2006;3(7):641-4.
2. Bilton D, Jones AL. Bronchiectasis: Epidemiology and causes. Eur
Respir Monogr Eur Respir Mon 2011;52:1-10.
3. Pasteur MC, Bilton D, Hill AT. British thoracic society bronchiectasis
non-CF guideline Group. British thoracic society guideline for non-CF
bronchiectasis. Thorax 2010;65 Suppl 1:i1-58.
4. Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and
economic burden of bronchiectasis. Am J Respir Crit Care Med
2004;169:A330.
5. Ringshausen FC, de Roux A, Pletz MW, Hamalainen N, Welte T,
Rademacher J. Bronchiectasis-associated hospitalizations in Germany,
2005-2011: A population-based study of disease burden and trends.
PLoS One 2013;8(8):e71109.
6. Hill AT, Welham S, Reid K, Bucknall CE. British thoracic society national
bronchiectasis audit 2010 and 2011. Thorax 2012;67(10):928-30.
7. Bopaka RG, Khattabi WE, Janah H, Jabri H, Afif H. Bronchiectasis:
A bacteriological profile. Pan Afr Med J 2015;22:378.
8. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.
9. Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R.
Determinants of chronic infection with Staphylococcus aureus in
patients with bronchiectasis. Eur Respir J 1999;14:1340-4.
10. Bronchiectasis. In: European Lung White Book. Available from: http://
www.erswhitebook.org/chapters/bronchiectasis/. [Last accessed on
2016 Sep 21].
11. Chaudhary M, Payasi A. A randomized, open-label, prospective,
multicenter phase-III clinical trial of Elores in lower respiratory tract
and urinary tract infections. J Pharm Res 2013;6:409-14.
12. Seitz AE, Olivier KN, Steiner CA, de Oca RM, Holland SM, Prevots DR.
Trends and burden of bronchiectasis-associated Hospitalizations in the
United States, 1993-2006. Chest 2010;138(4):944-9.
13. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Joint
taskforce of the European respiratory society and European society
for clinical microbiology and infectious diseases. Guidelines for the
management of adult lower respiratory tract infections. Clin Microbiol
Infect 2011;17(6):E1-59.
14. Byarugaba DK. Mechanisms of antimicrobial resistance. In: Sosa AJ,
Byarugaba DK, Amabile C, editors. Antimicrobial Resistance in
Developing Countries. Springer Science Business Media, LLC; 2009.
DOI 10.1007/978-0-387-89370-9_2.
15. Chaudhary M, Kumar S, Payasi A. A novel approach to combat acquired
multiple resistance in Escherichia coli by using EDTA as efflux pump
inhibitor. J Microb Biochem Technol 2012;4:126-30.
16. Chaudhary M, Kumar S, Payasi A. Role of CSE1034 in Escherichia coli
biofilm destruction. J Microb Biochem Technol 2013;5:54-8.
17. Chaudhary M, Sudaroli M, Kumar S, Krishnaraju V. Catering ESBL
resistance challenge through strategic combination of ceftriaxone,
sulbactam and ethylenediamine tetraacetic acid. Int J Drug Dev Res
2012;4(1):72-81.
18. Chaudhary M, Payasi A. Ethylenediamine tetraacetic acid: A non
antibiotic adjuvant enhancing Pseudomonas aeruginosa susceptibility.
Afr J Microbiol Res 2012;6:6799-804.
19. Monograph. Baddi, India: Venus Medicine Research Center.
20. Chaudhary M, Payasi A. Molecular characterization and in vitro
susceptibilities of β-lactamase producing Escherichia coli, Klebsiella
species, Acinetobacter baumannii, Pseudomonas aeruginosa and
Staphylococcus aureus to CSE1034 and other β-lactams. Asian Pac J
Trop Med 2014;7:S217-23.
21. Wedzicha JA. Oral corticosteroids for exacerbations of chronic
obstructive pulmonary disease. Thorax 2000;55:S23-7.
Statistics
385 Views | 284 Downloads
Citatons
How to Cite
Sharma, P. “INFECTIOUS EXACERBATION OF BRONCHIECTASIS SUCCESSFULLY TREATED WITH CEFTRIAXONE/SULBACTAM/DISODIUM EDETATE-1034 (ELORESâ„¢)”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 3, Mar. 2017, pp. 3-5, doi:10.22159/ajpcr.2017.v10i3.15791.
Section
Case Study(s)